MIRUM PHARMACEUTICALS INC (MIRM)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MIRM
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MIRM | Chair of the Board | 73 | ["Co-founder of the company","Former Executive Chairman","Extensive experience in the pharmaceutical and biotechnology industries","Held senior positions at various companies","Past President and CEO roles at multiple pharmaceutical firms"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BMRN | Chairman, Mirum Pharmaceuticals, Inc.; Lead Director, Horizon Therapeutics plc; Executive Chairman, Spruce Biosciences, Inc.; Director, Mirati Therapeutics Inc. | 68 | ["Chairman, Mirum Pharmaceuticals, Inc.","Lead Director, Horizon Therapeutics plc","Executive Chairman, Spruce Biosciences, Inc.","Director, Mirati Therapeutics Inc.","Extensive experience in managing biotechnology and pharmaceutical organizations","Business development","Compensation matters and finance and accounting","Executive Chairman at multiple biopharmaceutical companies","Former President and Chief Executive Officer of Lumena Pharmaceuticals, Inc.","Former President and Chief Executive Officer of SGX Pharmaceuticals, Inc.","Venture Partner at Pappas Ventures"] | ["Compensation Committee"] | 2021 |
Biography sourced from the proxy statement filing.
Michael Grey is our co-founder and has served as Chair of the Board since January 2020. Mr. Grey previously served as our Executive Chairman from March 2019 to December 2019 and as our Chief Executive Officer from our inception in May 2018 to March 2019. Mr. Grey has served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010. Mr. Grey served from January 2019 to September 2019 as President and Chief Executive Officer of Curzion Pharmaceuticals, Inc., a pharmaceutical company (sold to Horizon Therapeutics plc in April 2020), from October 2015 to January 2017 as President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., and from September 2014 to December 2017 as Chairman and Chief Executive Officer of Reneo Pharmaceuticals, Inc. From February 2011 to June 2014, Mr. Grey served as President and Chief Executive Officer of Lumena Pharmaceuticals, Inc., which was acquired by Shire plc in June 2014. Mr. Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly and Company in 2008), President and Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001) and President of BioChem Therapeutic Inc. Prior to these, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr. Grey currently serves on the board of directors of public companies OnKure Therapeutics, Inc. (formerly Reneo), and Spruce Biosciences, Inc., as well as privately held biotechnology companies Alethio Therapeutics, Ltd., Altay Therapeutics Inc., Plexium Inc., Sorriso Pharmaceuticals, Inc. and Theolytics Ltd. Mr. Grey served as a member of the board of directors for BioMarin Pharmaceuticals, Inc. from 2005 to 2021, Horizon Therapeutics plc from 2011 to 2023, Mirati Therapeutics, Inc. from 2014 until 2021 and Amplyx Pharmaceuticals, Inc. from January 2017 to April 2021. Mr. Grey received his B.S. in chemistry from the University of Nottingham in the United Kingdom. Skills and Qualifications specific to Mirum Pharmaceuticals, Inc.: The Board and Nominating Committee believe that Mr. Grey s perspective and experience as our co-founder and former Executive Chairman, as well as his extensive experience managing and leading both early stage and established companies within the pharmaceutical and biotechnology industries qualifies him to serve on the Board.